THZ531
THZ531 is a selective and covalent inhibitor of both CDK12 and CDK13 with IC50s of 158 nM and 69 nM, respectively[1].
Product Specifications
CAS Number
1702809-17-3
UNSPSC
12352005
Hazard Statement
H315, H317, H318, H334, H335, H341, H361, H370, H413
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/THZ531.html
Purity
99.86
Solubility
DMSO : 250 mg/mL (ultrasonic)
Smiles
ClC(C(C1=CNC2=CC=CC=C12)=N3)=CN=C3N[C@@H]4CCCN(C(C5=CC=C(NC(/C=C/CN(C)C)=O)C=C5)=O)C4
Molecular Formula
C30H32ClN7O2
Molecular Weight
558.07
Precautions
H315, H317, H318, H334, H335, H341, H361, H370, H413
References & Citations
[1]Zhang T, et al. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat Chem Biol. 2016 Oct;12 (10) :876-84.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK12; CDK13; CDK7; CDK9
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Sifalimumab (Biosimilar Reference Antibody) (IFNA1)
Sifalimumab (Biosimilar Reference Antibody) (IFNA1)